IP Library Granted Patent US 7,524,515
Granted Patent B2
US 7,524,515 · App. 10/339,977 · Granted Apr 28, 2009

Pharmaceutical safety dosage forms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,515
App. No.
10/339,977
Granted
Apr 28, 2009
Kind
B2
Abstract

Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided.

Claims (7)

1. A method of delivering an adrenergic beta-blocker to a patient comprising placing an adrenergic beta-blocker into a pharmaceutical safety dosage form comprising a sympathomimetic, wherein said sympathomimetic is dopamine, epinepherine, derivatives thereof, or combinations thereof and wherein said sympathomimetic has significant bioavailability only when said dosage form is disrupted; and administering said safety dosage form to the patient.

2. The method of claim 1 wherein said adrenergic beta-blocker is propranolol, metoprolol, timolol maleate, derivatives thereof, or combinations thereof.

3. A pharmaceutical safety dosage form comprising an adrenergic beta-blocker and an antagonist wherein said antagonist comprises a sympathomimetic, wherein said sympathomirnetic is doparnine, epinephrine, derivatives thereof, or combinations thereof and wherein said sympathomimetic has significant bioavailability only when said pharmaceutical safety dosage form is disrupted.

4. The pharmaceutical safety dosage of claim 3 wherein said pharmaceutical is adapted for time-release, or said antagonist comprises an insoluble coating, or both.

5. The pharmaceutical safety dosage form of claim 3 wherein said bioavailability occurs upon mechanical disruption.

6. The pharmaceutical safety dosage form of claim 3 adapted to be administered orally.

7. The pharmaceutical safety dosage form of claim 3 wherein said adrenergic beta-blocker is propranolol, metoprolol, timolol maleate, derivatives thereof, or combinations thereof.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2021
From: TAKEDA PHARMACEUTICALS USA, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056831/0119 →
CHANGE OF NAME Recorded Nov 30, 2012
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029377/0901 →
MERGER Recorded Nov 30, 2012
From: MPC OLDCO, INC.
To: MPC MERGER SUB, INC.
Reel/Frame 029380/0671 →
MERGER Recorded Nov 30, 2012
From: MPC MERGER SUB, INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 029380/0855 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026744/0541 →
RELEASE OF SECURITY INTEREST Recorded Aug 4, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026702/0112 →
PATENT SECURITY AGREEMENT Recorded Jan 30, 2007
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 018826/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2004
From: ROBERTS, RICHARD H.
To: MUTUAL PHARMACEUTICALS, INC.
Reel/Frame 015344/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2003
From: ROBERTS, RICHARD H.
To: MUTUAL PHARMACEUTICALS, INC.
Reel/Frame 014223/0430 →